 Foscarnet sodium Cytomegalovirus CMV major opportunistic viral pathogen disease immunocompromised patients organ transplant recipients people AIDS pneumonitis gastrointestinal disease encephalitis common manifestation patients AIDS retinitis untreated retinal necrosis Ganciclovir sodium licensed antiviral agent treatment CMV retinitis infection majority AIDS patients significant granulocytopenia thrombocytopenia therapy clinical application Myelosuppression AIDS patients agents zidovudine trimethoprim/sulfamethoxazole necessitating dosage reductions discontinuation agents patients ganciclovir Foscarnet sodium pyrophosphate analog active cytomegalovirus human immunodeficiency virus type HIV effective alternative management CMV retinitis Trials intravenous foscarnet CMV retinitis favorable results initial daily doses mg/kg/d intermittent infusions hours maintenance regimens mg/kg/d single daily one- two-hour infusions Foscarnet therapy renal impairment intravenous maintenance therapy recurrence CMV infection drawbacks foscarnet lack major myelosuppressive toxicity activity HIV replication safe effective alternative agent management CMV infection AIDS patients